[Thrombolytic, antiplatelet and anticoagulant therapy for thrombotic disorders].
In the antithrombotic therapy, it's important to evaluate the role of thrombus in the present clinical status of thrombotic vascular diseases such as acute arterial occlusion, arteriosclerosis obliterans or deep vein thrombosis. For this purpose, coagulofibrinolytic immunochemical molecular markers such as thrombin-antithrombin III complex and D dimer may be useful. These markers are also useful for the evaluation of therapeutic effect. For the extremely severe ischemic limb, survey and treatment of transient atrial fibrillation and possible embolic source in heart, aorta or arteries are indispensable. Moreover, coagulation abnormalities (congenital antithrombin III, protein C, protein S deficiency or acquired anti-phospholipid syndrome) or basic immunologic disorders (Takayasu's arteritis, Behçet disease or other autoimmune diseases) should be carefully excluded or properly controlled.
Homma
S
S
Department of Critical Care Medicine, University of Tsukuba.
Yamaguchi
I
I
D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors